Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Montalban, Xavier, Piasecka-Stryczynska, Karolina, Kuhle, Jens · Multiple Sclerosis Journal · 2024